Summary & Overview

HCPCS Q0155: Dronabinol (Syndros) 0.1 mg Oral Anti‑emetic

HCPCS Level II code Q0155 identifies dronabinol (Syndros) 0.1 mg oral formulation when used specifically as a complete therapeutic substitute for an intravenous anti-emetic during chemotherapy, limited to a 48-hour regimen. The code designates a medication-based service intended to replace IV anti-emetic administration in the peri-chemotherapy window, with implications for site-of-service billing, medication sourcing, and clinical workflows in oncology infusion settings. Nationally, this code matters because it clarifies billing for an oral alternative to IV anti-emetics and affects coverage and benefit design for cancer supportive care.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn the clinical context for use of dronabinol (Syndros) as an IV substitute, typical sites of service where the code applies, and what to expect in payer coverage and billing practice at a national level. The publication provides benchmarks for utilization and reimbursement where available, summarizes relevant policy considerations for medication substitution during chemotherapy, and outlines coding and billing implications for oncology service lines. Data limitations and missing input elements are noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareQ0155HCPCS Level IIdronabinolanti-emeticoncologychemotherapy supportive careoral medicationinfusion suitedrug substitutionoutpatient treatment

Billing Code Overview

HCPCS Level II code Q0155 represents dronabinol (Syndros), 0.1 mg, oral, an FDA-approved prescription anti-emetic formulated for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, with administration limited to not to exceed a 48-hour dosage regimen.

Service Type: Oral anti-emetic medication used as an IV substitute during chemotherapy administration.

Typical Site of Service: Oncology infusion suites and outpatient chemotherapy treatment settings where intravenous anti-emetic therapy would otherwise be provided.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult oncology patient receiving moderately or highly emetogenic chemotherapy in an outpatient infusion center or hospital outpatient department. During chemotherapy administration the patient experiences acute nausea and vomiting refractory to first-line IV anti-emetics (e.g., ondansetron, dexamethasone). The treating oncologist or infusion nurse documents the failure or intolerance to IV therapy and elects to administer an oral FDA‑approved dronabinol formulation as a complete therapeutic substitute for an IV anti‑emetic for the duration of the chemotherapy episode, not to exceed a 48‑hour regimen per the billing descriptor for Q0155.

Typical clinical workflow:

Patient receives chemotherapy in an outpatient infusion center or hospital outpatient department.
Nursing documents vital signs, chemotherapy regimen, and anti‑emetic plan in the infusion record.
If IV anti‑emetic administration is contraindicated (e.g., IV access issues, severe IV drug reaction) or ineffective, the clinician orders oral dronabinol Q0155 per protocol.
Pharmacy verifies the order, dispenses the oral dronabinol unit dose, and labels it for use as a complete substitute for the IV anti‑emetic for up to 48 hours.
Nursing administers and documents the medication, monitors anti‑emetic effect, and records any adverse reactions.
Billing posts the HCPCS Level II code Q0155 with applicable modifiers and links to the primary chemotherapy encounter and relevant diagnosis code(s) for nausea and vomiting related to chemotherapy.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard service	Use when no special modifier applies to the `Q0155` service.
`22`	Increased procedural service	Use when services required for administration/documentation are substantially greater than usual (rare for this oral single‑dose regimen).
`23`	Unusual anesthesia	Not typically applicable; include only if anesthesia was provided unusually during the encounter.
`52`	Reduced services	Use when the service was partially reduced or not completed as originally planned.
`53`	Discontinued procedure	Use if the planned substitution was started but discontinued due to patient reaction or other issue.
`62`	Two surgeons	Not typically applicable; use only if two surgeons are involved in the encounter (rare for this medication).
`78`	Unplanned return to operating room	Not applicable except in unusual cases with surgical complications following chemotherapy.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery	Not applicable for medication administration in infusion setting.
`QX`	Requirement for modifier - assistant surgeon (optional)	Not applicable for this service; included for completeness when assistants bill.
`QY`	CLIA waived test performed by technician	Use when a waived point‑of‑care test is performed in the same encounter (rare connection).
`CO`	Worker’s compensation	Use when payer relationship is worker’s compensation.
`CQ`	Monitored anesthesia care service by an anesthesiologist or nurse anesthetist	Not typical for this medication but used when monitored anesthesia care is provided.
`FX`	Correction to prior claim	Use when correcting a previously submitted claim for `Q0155`.
`FY`	High cost or unusual drugs reporting	Use when payer requires a modifier to identify high‑cost or special drugs (payer‑specific).

Taxonomy Code	Specialty	Notes
`208000000X`	Medical Oncology	Primary specialty managing chemotherapy and anti‑emetic therapy.
`363L00000X`	Infusion Therapy	Nurses and infusion specialists who administer and monitor IV/PO anti‑emetics.
`207Q00000X`	Hematology/Oncology	Hematology/oncology specialists providing chemotherapy care.
`309K00000X`	Pharmacy	Clinical pharmacists verifying and dispensing the oral dronabinol.
`222N00000X`	Nurse Practitioner	Advanced practice providers who may order and document anti‑emetic substitutions.

ICD-10 Code	Description	Clinical Relevance
`R11.0`	Nausea	Common acute symptom for which an anti‑emetic substitute such as `Q0155` may be used during chemotherapy.
`R11.2`	Nausea with vomiting, unspecified	Typical coding when patients experience both nausea and vomiting related to chemotherapy.
`R11.10`	Vomiting, unspecified	Used when vomiting is the primary complaint necessitating anti‑emetic therapy.
`T45.1X5A`	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter	Relevant when coding adverse effects from chemotherapy that may include severe nausea/vomiting requiring alternative anti‑emetics.
`Z51.11`	Encounter for antineoplastic chemotherapy	Primary encounter code to link the chemotherapy administration visit where `Q0155` is used as a substitute.

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, infusion technique; each additional hour (list separately in addition to primary service)	Often billed for the ongoing chemotherapy infusion during which `Q0155` is used as an anti‑emetic substitute.
`96415`	Chemotherapy administration; maximum two hour infusion of single or combined chemotherapeutic agent(s)	Billed for short chemotherapy infusion services occurring in the same encounter as `Q0155`.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify drug); subcutaneous or intramuscular	May be billed for concurrent parenteral anti‑emetics if given in addition to oral dronabinol (documentation required).
`99070`	Supplies and materials (e.g., drugs, devices) provided by the physician other than those usually included with the office visit or procedure	May be used to report non‑covered supplies when payer policy requires separate reporting alongside `Q0155`.
`96401`	Chemotherapy administration, intravenous infusion technique, up to 1 hour	Represents primary chemotherapy infusion codes billed in the same visit where `Q0155` is administered.

OpenPayer